Education
About Us
Working with TipRanks
Follow Us
Citius Pharma (CTXR)
:CTXR
CTXR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $23.20
Previous CloseN/A
Volume111.57K
Average Volume (3M)1.11M
Market Cap
$14.30M
Enterprise Value$16.61M
Total Cash (Recent Filing)$1.10M
Total Debt (Recent Filing)$204.57K
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Feb 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,174,466
10 Day Avg. Volume296,872
30 Day Avg. Volume1,113,738
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue106.51
Enterprise Value/Gross Profit-158.29
Enterprise Value/Ebitda-0.39
Forecast
1Y Price Target
$6.00Price Target Upside365.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical Trials And DataMino-Lok demonstrated an improvement in treatment of CRBSI, achieving its primary endpoint in the P3 study.
Commercialization PotentialCitius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.
Regulatory ProgressThe FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.
Bears Say
Financial ConstraintsCitius Pharma reported a net loss with very limited cash, indicating the need to raise capital soon.
Financial PerformanceThe company's recent quarterly report suggests the need for additional capital in the immediate future to support operations.
Regulatory DelaysCompleting the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.
Citius Pharmaceuticals News
CTXR FAQ
What was Citius Pharma’s price range in the past 12 months?
Citius Pharma lowest stock price was $0.65 and its highest was $23.20 in the past 12 months.
What is Citius Pharma’s market cap?
Citius Pharma’s market cap is $14.30M.
When is Citius Pharma’s upcoming earnings report date?
Citius Pharma’s upcoming earnings report date is Feb 06, 2026 which is in 182 days.
How were Citius Pharma’s earnings last quarter?
Currently, no data Available
Is Citius Pharma overvalued?
According to Wall Street analysts Citius Pharma’s price is currently Undervalued.
Does Citius Pharma pay dividends?
Citius Pharma does not currently pay dividends.
What is Citius Pharma’s EPS estimate?
Citius Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Citius Pharma have?
Citius Pharma has 11,174,466 shares outstanding.
What happened to Citius Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Citius Pharma?
Currently, no hedge funds are holding shares in CTXR
Citius Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (365.12% Upside)
$6.00 (365.12% Upside)
Blogger Sentiment
Bullish
CTXR Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 12.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.30%
12-Months-Change
Fundamentals
Return on Equity
-60.06%
Trailing 12-Months
Asset Growth
33.92%
Trailing 12-Months
Company Description
Citius Pharma
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
CTXR Stock 12 Month Forecast
Average Price Target
$6.00
▲(365.12% Upside)
Technical Analysis
Plus Therapeutics
―
MetaVia
―
Marker Therapeutics
―
Spruce Biosciences
―
SAB Biotherapeutics
―
Ownership Overview
Currently, No data available
---